Baymatob’s Oli procures $6.5m to monitor the leading cause of preventable maternal death

Clare Ventures’ portfolio partner Baymatob has successfully closed a major funding round which is set to accelerate their entry into the US market.

The Sydney-based company is now involved in U.S. clinical trials, as well as trials at the Royal North Shore and Royal Hospital for Women in Sydney for their Oli device which was awarded a ‘Breakthrough Device Designation’ by the FDA, in 2021.

Click through to read the article from Forbes:

Sydney’s Oli procures $6.5m to monitor the leading cause of preventable maternal death